Of interest, BGB‐283 significantly lowered the EC50 of selumetinib in twelve out of sixteen K/N‐RAS mutant NSCLC and CRC cell lines, with maximum EC50 difference ranging from 9‐ to over 100‐fold (Table 2). This evidence concerns the gene NRAS and non-small cell lung carcinoma.